STAT Plus: Zai Lab targets blood cancers in deal with Regeneron
WELLCOME COLLECTION
Shanghai's Zai Lab is adding a blood cancer drug to its pipeline through a licensing deal with the U.S. biotech giant Regeneron.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario